Gefitinib (Iressa™) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
that offers treatment for patients with locally advanced or metastatic non-small cell lung …

Epidermal growth factor receptor (EGFR) has been extensively studied as a target in the
treatment of non-small cell lung cancer. Gefitinib (ZD 1839, Iressa) and erlotinib (OSI 774 …

Background Gefitinib is active in patients with pretreated non-small-cell lung cancer
(NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced …

The medical treatment of non-small-cell lung cancer (NSCLC) has progressively changed
since the introduction of “targeted therapy”. The development of one of these molecular drug …

Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …

Fifteen% or fewer of patients with non-small cell lung cancer (NSCLC) survive 5 years. The
current standard of care for patients with locally advanced or metastatic NSCLC is systemic …

PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …

Introduction: Epidermal growth factor receptor-tyrosine kinase inhibitors are used as
effective first-line and salvage therapy in the treatment of advanced non-small cell lung …

Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

This study aimed to perform a meta-analysis comparing the efficacy and safety of gefitinib in
combination with chemotherapy versus gefitinib alone in patients with advanced Non-Small …